The Danish pharmaceutical industry has received a new European approval, which means that Denmark is well on its way to introducing manufacturer-paid bar codes on medicine that the EU requires to be introduced before February 2019, and which has cost Novo an investment of more than DKK 100 million (USD 16.6 million).
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.
En "digital transformation" i Novo Nordisks F&U-afdeling, som koster 400 medarbejdere jobbet, stjal fokus i uge 38, hvor Zealand Pharma ramte plet i et afgørende fase 3-studie og Coloplast holdt kapitalmarkedsdag. MedWatch giver dig her overblikket over ugens vigtigste begivenheder.